Clinical trials Below are current clinical trials.40 studies in Endocrinology (open studies only). Filter this list of studies by location, status and more. Glycemic Variability Assessment in Complex Diabetes During Hospitalization Rochester, Minn. The purpose of this study is to assess the glycemic variability in patients with complex diabetes admitted in the hospital using a glycemic sensor. A Study of Immune Cell Abnormalities Found in Individual Patients who have Type 1 Diabetes and are Waiting for Pancreas or Pancreas/Kidney Transplant Surgery Rochester, Minn. The purpose of this study is to measure and characterize specific immune cell abnormalities found in patients who have type 1 diabetes and may or may not be on the waiting list for either a pancreas alone or a pancreas and kidney transplant. A Study to Evaluate the Therapeutic Effectiveness of Rifaximin in Diabetic Gastroparesis Patients Using Bloating as the Primary Endpoint Jacksonville, Fla. The primary purpose of this study is to prospectively assess symptoms of bloating (severity, prevalence) in patients with diabetic gastroparesis. Risk and Benefit Assessment of Pancreas Transplantation Rochester, Minn. The purpose of this study is to (i)assess glucose variability at pre specified time points after Pancreas Transplantation (ii) collect pre-specified serious adverse events after PT and in appropriate control groups (iii) assess mixed meal dynamics after pancreas transplantation. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the response rate of the combination of Pemetrexed and Pembrolizumab in patients with recurrent or metastatic salivary gland cancer (R/M SGC). To Assess the Effectiveness, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva Rochester, Minn. The purpose of this study is to evaluate the effectiveness, safety, tolerability, and PK of INCB000928 over a 24-week treatment period followed by a 52-week, open-label extension period. Prospective Study of Adrenal Disorders: Clinical Registry, Imaging Analysis and Biomaterial Collection Rochester, Minn. The purpose of this research is to follow people with adrenal disorders in order to make conclusions about the natural history of a particular adrenal disease as well as effect of various therapies and interventions decided on by you and your medical team. In addition, we will collect biomaterial from you at times you are being evaluated which will be used to discover novel biomarkers which can potentially improve the accuracy of current diagnostic tests and affect the management of patients with adrenal disorders. We will also include a control group (without known adrenal disease) to compare to the volunteers with adrenal disorders. Feasibility of a Constant Pressure Skin Disk (CPSD) in Enteral Tubes Rochester, Minn. The purpose of this research study is to gather information on one specific part of a feeding tube, known as the adjustable skin disk. The goal of this research study is to see if a new type of adjustable skin disk, called a Constant Pressure Skin Disk (CPSD), can safely and effectively support one or more of the following: 1) adequate healing after feeding tube placement; 2) a reduced rate of complications associated with feeding tubes, such as leakage, skin breakdown, etc.; 3) ease of use; and 4) durability (holds up to usual wear and tear associated with feeding tube use). Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1 Scottsdale/Phoenix, Ariz. This study is being done to better understand the relationship between inflammation in your AT, abnormal deposition of fat around your liver and how this affects its appearance and function and ultimately insulin resistance. Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids Rochester, Minn. Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking is responsible for muscle insulin resistance, although it has been shown that raising FFA with Intralipid can cause muscle insulin resistance within 4 hours. We do not understand to what extent the incorporation of FFA into ceramides or diacylglycerols (DG) affect insulin signaling and muscle glucose uptake. We propose to alter the profile and concentrations of FFA of healthy, non-obese adults using an overnight, intra-duodenal palm oil infusion vs. an intra-duodenal Intralipid infusion (both compared to saline control). We will compare the muscle FFA storage into intramyocellular triglyceride, intramyocellular fatty acid trafficking, activation of the insulin signaling pathway and glucose disposal rates, providing the first measure of how different FFA profiles alter muscle FFA trafficking and insulin action at the whole body and cellular/molecular levels. By identifying which steps in the insulin signaling pathway are most affected, we will determine the site-specific effect of ceramides and/or DG on different degrees of insulin resistance. Hypothesis 1: Palm oil infusion will result in abnormal FFA trafficking into intra-myocellular ceramides and abnormal insulin signaling. Hypothesis 2: Intralipid infusion will result in abnormal FFA trafficking into intra-myocellular saturated DG and abnormal insulin signaling. Pagination Clinical studies PrevPrevious Page Go to page 22 Go to page 33 Go to page 44 Request an appointment Specialty groupsResearch Nov. 02, 2019 Share on: FacebookTwitter EndocrinologySectionsOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20392484 Medical Departments & Centers Endocrinology